Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2003 October;138(5) > Giornale Italiano di Dermatologia e Venereologia 2003 October;138(5):377-83

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

REVIEWS  


Giornale Italiano di Dermatologia e Venereologia 2003 October;138(5):377-83

Copyright © 2003 EDIZIONI MINERVA MEDICA

language: Italian

The intravenous immunoglobulin in dermatology

Caproni M., Pestelli E., Fabbri P.

Dipartimento di Scienze Dermatologiche II Clinica Dermatologica Università degli Studi di Firenze, Firenze


PDF  


The intravenous immunoglobulin (IvIg) are increasingly used to treat a range of inflammatory and autoimmune diseases. Actually, the dermatological uses of IvIg include the treatment of dermatomyositis, the autoimmune bullous disorders, pyoderma gangrenosum, and recently also atopic dermatitis and autoimmune urticaria. Several immunomodulatory mechanisms have been proposed for IvIg, herein discussed treatment protocols and adverse effects. The increasing use of this therapy has helped to establish its excellent safety record without the many adverse effects of steroids and other immunosuppressive agents. However, the majority of the evidence was limited to anecdotal case reports or uncontrolled trials. Dermatomyositis is the exception, with a single controlled trial demostrating its excellent positive effect. In consideration of the high total cost of the therapy, further placebo-controlled trials should be performed to better select the employment of this safety treatment.

top of page

Publication History

Cite this article as

Corresponding author e-mail